A phase I study to assess the safety and immunogenicity of Ad6NSmut and AdCh3NSmut in patients with hepatitis C virus infection.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2015
At a glance
- Drugs Hepatitis C vaccine (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- 20 Mar 2015 Accrual to date 150% reported by United Kingdom Clinical Research Network record.
- 06 May 2013 Planned end date changed from 1 Jun 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 04 Oct 2012 Planned End Date changed from 31 Dec 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.